This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Stealth BioTherapeutics Crecimiento futuro
Future controles de criterios 0/6
Información clave
3.4%
Tasa de crecimiento de los beneficios
95.1%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 24.5% |
Tasa de crecimiento de los ingresos | n/a |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company
Sep 30Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private
Aug 01Stealth BioTherapeutics: A Net-Net Biopharma Going Private
Jul 26Stealth BioTherapeutics receives Nasdaq non-compliance receipt
Jul 11Stealth Biotherapeutics shares soar on EMA orphan drug status for elamipretide
Jun 01Stealth BioTherapeutics skyrockets on data for elamipretide studies
May 06FDA accepts Stealth Bio's Pre-NDA meeting request for elamipretide
Jan 06Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year
Dec 31Stealth Bio launches $3.2M registered direct offering
Nov 20Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2024 | N/A | -48 | N/A | N/A | 1 |
12/31/2023 | N/A | -48 | N/A | N/A | 2 |
12/31/2022 | N/A | -45 | N/A | N/A | 2 |
12/31/2021 | N/A | -53 | -45 | -45 | N/A |
9/30/2021 | N/A | -51 | N/A | N/A | N/A |
6/30/2021 | N/A | -56 | -44 | -44 | N/A |
3/31/2021 | N/A | -50 | N/A | N/A | N/A |
12/31/2020 | N/A | -57 | -54 | -54 | N/A |
9/30/2020 | 21 | -35 | -39 | -38 | N/A |
6/30/2020 | 21 | -41 | N/A | N/A | N/A |
3/31/2020 | 21 | -44 | N/A | N/A | N/A |
12/31/2019 | 21 | -72 | -48 | -48 | N/A |
9/30/2019 | N/A | -102 | -75 | -74 | N/A |
6/30/2019 | N/A | -108 | N/A | N/A | N/A |
3/31/2019 | N/A | -120 | N/A | N/A | N/A |
12/31/2018 | N/A | -97 | -72 | -72 | N/A |
9/30/2018 | N/A | -92 | -69 | -69 | N/A |
12/31/2017 | N/A | -83 | -70 | -70 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: MITO is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: MITO is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: MITO is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if MITO's revenue is forecast to grow faster than the US market.
Ingresos de alto crecimiento: MITO is forecast to have no revenue next year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if MITO's Return on Equity is forecast to be high in 3 years time